Senior Clinical Project Manager (Remote)

Job Description
Orano Med:
Orano Med has developed new processes for producing high-purity lead-212, a rare radioactive isotope. Lead-212 is currently at the heart of promising research projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells.

Position Summary:
The Senior Clinical Project Manager is responsible for project management and oversight of assigned clinical trials.

Position Responsibilities:

• Oversight checks including monitoring report review and TMF checks.
• Status meeting attendance, meeting minute review/taking.
• Invoice review, confirmation of services received.
• Support CRO with site level issues including non-compliance, etc.
• Review data cleaning metrics, address backlogs.
• Review or create/amend study level documents including ICFs, protocols, study plans, training materials, etc.
• Provide study status updates.
• Manage study to budget and timelines.
• Other duties as assigned.
• Will be a remote position***

All candidates must meet the following minimum requirements in order to be considered for this opportunity. Candidates who exceed minimum qualifications may be considered for a higher level position.
Minimum Qualifications:

• Bachelor’s degree in life/physical sciences or nursing.
• 10-12 years, with at least 3 years of experience as a CTM / Clinical Trial Project Manager

Differentiating Qualifications:

• Previous experience working with a CRO.

Skills/Knowledge:

• Knowledgeable in ICH GCP, applicable US regulations, project management and clinical operations, study budgets and timelines.
• Knowledgeable on platforms including Medidata RAVE, clinical trial management systems, excel, etc.

Orano Med LLC
Orano Med is at the forefront of research in nuclear medicine and is developing new therapies against cancer. Based on its unique expertise in the production of lead-212 (Pb-212) and radiolabeling technologies, Orano Med is developing innovative radioligand therapies which consist of selectively destroying cancer cells while limiting the impact on surrounding healthy cells. With a solid portfolio of molecules in development capable of targeting various forms of cancer, and a reliable supply chain for Pb-212, Orano Med aims to become a leader in targeted alpha therapies, in particular for patients with currently unmet medical needs.

Find out more about Orano Med